Last $13.46 USD
Change Today -0.43 / -3.10%
Volume 608.1K
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

biodelivery sciences intl (BDSI) Snapshot

Open
$13.93
Previous Close
$13.89
Day High
$14.05
Day Low
$13.14
52 Week High
07/15/14 - $14.44
52 Week Low
11/14/13 - $4.16
Market Cap
663.6M
Average Volume 10 Days
604.4K
EPS TTM
$-0.93
Shares Outstanding
49.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODELIVERY SCIENCES INTL (BDSI)

biodelivery sciences intl (BDSI) Related Businessweek News

No Related Businessweek News Found

biodelivery sciences intl (BDSI) Details

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

biodelivery sciences intl (BDSI) Top Compensated Officers

Chief Executive Officer, President, Chief Sci...
Total Annual Compensation: $739.3K
Executive Chairman and Member of Executive Su...
Total Annual Compensation: $368.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $61.2K
Executive Vice President of Product Developme...
Total Annual Compensation: $438.2K
Compensation as of Fiscal Year 2013.

biodelivery sciences intl (BDSI) Key Developments

BioDelivery Sciences International, Inc. Provides Update on Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. announced that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The interim analysis was performed on data from the first 50% of patients who completed the study. The purpose of the interim analysis was to allow for a sample size adjustment if necessary to maintain appropriate statistical power to detect a treatment effect between Clonidine Topical Gel and placebo. BDSI views the outcome of the analysis as very encouraging. As a result of the interim analysis, a total of approximately 80 additional patients will be added to the ongoing trial in an effort to maintain 90% power to detect a statistically significant difference between Clonidine Topical Gel and placebo. The analysis was executed by an independent biostatistician.

BioDelivery Sciences International, Inc. Announces Board of Directors Appointments

BioDelivery Sciences International, Inc. announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. Mr. Bramlage is currently the Chief Executive Officer of Pearl Therapeutics, Inc. Dr. Feinberg is a noted specialist in the area of pain management where he is board certified. Since 2008, he has served as a member of the Board of Directors and Medical Executive Committee of the Frontenac Surgery and Spine Care Center in St. Louis, Missouri.

BioDelivery Sciences International, Inc. Announces Retirement of William S. Poole, Director

On July 17, 2014, BioDelivery Sciences International, Inc. held its 2014 Annual Meeting of Stockholders. As previously announced, at the Annual Meeting, the term of William S. Poole, a current director of the company, expired due to his retirement from the Board in good standing. Such retirement was effective as of the conclusion of the Annual Meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDSI:US $13.46 USD -0.43

BDSI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BDSI.
View Industry Companies
 

Industry Analysis

BDSI

Industry Average

Valuation BDSI Industry Range
No financial data is available for BDSI.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODELIVERY SCIENCES INTL, please visit www.bdsi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.